Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus paracasei + lactobacillus casei 431 + lactobacillus fermentum PCC
- Development stage
- Unknown
- Lead developer
- Novonesis
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This combination is a multi-strain probiotic formulation designed to support immune system function and gastrointestinal health. It features two clinically studied trademarked strains: **Lactobacillus casei 431** (a strain of *Lactobacillus paracasei*) and **Lactobacillus fermentum PCC**. *L. casei 431* is recognized for its ability to stimulate the immune response, particularly by increasing secretory immunoglobulin A (sIgA) levels and reducing the duration of upper respiratory tract infections. *L. fermentum PCC* is a resilient strain isolated from human gut flora that survives gastric transit to colonize the intestine, where it modulates cytokine production and supports the body's natural defenses. The addition of generic *Lactobacillus paracasei* (often the Lpc-37 strain in commercial blends) further enhances the formulation's ability to maintain a healthy microbiome and support intestinal barrier integrity.
- Brand names
- Life-Space Immune Support Probiotic
- Other names
- Lactobacillus paracasei + Lactobacillus casei 431 + Lactobacillus fermentum PCCProbiotic Immune Formula
02
Targets
sIgA (Secretory immunoglobulin A)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on lactobacillus paracasei + lactobacillus casei 431 + lactobacillus fermentum PCC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus paracasei + lactobacillus casei 431 + lactobacillus fermentum PCC.